Antonio Maria Labate

Dr. Antonio Maria Labate

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2014 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
Giuseppina Tiziana RussoGiuseppina Tiziana Russo
Giuseppina Tiziana Russo
Antonio Maria LabateAntonio Maria Labate
Antonio Maria Labate
AGA. Giandalia
A. Giandalia
ERE. L. Romeo
E. L. Romeo
PVP. Villari
P. Villari
DCD. Cucinotta
D. Cucinotta

9 July 2017 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
MAMichela Adamo
Michela Adamo
Antonio Maria LabateAntonio Maria Labate
Antonio Maria Labate
AFAnna Ferrulli
Anna Ferrulli
CMConcetta Macrì
Concetta Macrì
ITIleana Terruzzi
Ileana Terruzzi
LLLivio Luzi
Livio Luzi

6 March 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
SCSilvana Costa
Silvana Costa
CMCesare Miranda
Cesare Miranda
AEAntonia Elefante
Antonia Elefante
VVValeria Vallone
Valeria Vallone
CVCarmela Vinci
Carmela Vinci
MSMarco Strazzabosco
Marco Strazzabosco

3 March 2026 in Endocrines
Verified
Journal Article
Open access
PDF file
Antonio Maria LabateAntonio Maria Labate
Antonio Maria Labate
LMLorenzo Moretti
Lorenzo Moretti
PVProvvidenza Villari
Provvidenza Villari
Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Although the evidence base for oral semaglutide is growing, data specifically in older adults remain relatively limited, particularly regarding long-term effectiveness and tolerability in routine practice. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was the achievement of HbA1c < 7% at 12 months. Multivariable logistic regression was performed to identify baseline predictors of response. Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m2, p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, baseline age, diabetes duration, baseline HbA1c and baseline VAI were not independently associated with the achievement of HbA1c < 7%; therefore, these baseline factors did not discriminate responders within our cohort (hypothesis-generating). Greater absolute HbA1c reductions were observed in patients with higher baseline HbA1c. Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.

Verified
Journal Article
Open access
PDF file
Antonio Maria LabateAntonio Maria Labate
Antonio Maria Labate
ECElena Cimino
Elena Cimino
LGLaura Giacomelli
Laura Giacomelli
SEStefano Ettori
Stefano Ettori
OOOladayo Adigun Oladeji
Oladayo Adigun Oladeji
BABarbara Agosti
Barbara Agosti
Cardiometabolic residual risk in type 2 diabetes mellitus (T2D) persists despite major advances in glucose-lowering therapy, lipid management, blood pressure control, weight reduction, and organ-protective strategies. This residual burden should not be interpreted solely as the consequence of incomplete achievement of conventional therapeutic targets, but rather as the clinical expression of persistent molecular activity involving multiple interconnected organs and pathways. Insulin resistance, metaflammation, oxidative stress, mitochondrial dysfunction, lipotoxicity, endothelial impairment, hepatic metabolic dysregulation, renal inflammation, fibrotic remodeling, and metabolic memory interact within a dynamic network linking adipose tissue, liver, kidney, immune cells, and vasculature. In this review, we discuss the biochemical and molecular drivers of cardiometabolic residual risk in T2D, with particular emphasis on impaired insulin receptor substrate/PI3K/Akt signaling, stress-kinase activation, NLRP3 inflammasome priming and assembly, MASLD-related lipotoxicity and fibrogenesis, podocyte and tubular injury, endothelial nitric oxide synthase uncoupling, AGE-RAGE signaling, and thrombo-inflammatory vascular injury. These pathways explain why biological vulnerability may persist even when conventional clinical parameters appear adequately controlled. We also examine the role of translational biomarkers and simple clinical indices, including TyG-derived indices, adiposity markers, hepatic steatosis and fibrosis scores, albuminuria, eGFR, and lipid-related markers, as accessible windows into active biological pathways. Finally, we review how contemporary therapeutic strategies may modulate selected components of this residual-risk network. A pathway-centered interpretation of T2D may support more precise residual-risk phenotyping and help move cardiometabolic care beyond isolated target control toward mechanism-based prevention. This review further links these mechanisms to the contemporary cardiovascular–kidney–metabolic (CKM) framework, as defined by the 2026 AHA/ACC/ADA/ASN CKM Guideline, and disaggregates the underlying molecular network into organ-specific pathway cascades that make the causal relationships between metabolic, inflammatory, hepatic, renal, and vascular injury more explicit.

31 July 2026 in Endocrines
Verified
Journal Article
Open access
PDF file
Antonio Maria LabateAntonio Maria Labate
Antonio Maria Labate
ECElena Cimino
Elena Cimino
LGLaura Giacomelli
Laura Giacomelli
SEStefano Ettori
Stefano Ettori
OOOladayo Adigun Oladeji
Oladayo Adigun Oladeji
BABarbara Agosti
Barbara Agosti
Type 2 diabetes mellitus is a highly prevalent, heterogeneous, and progressive chronic disease. In a large proportion of patients, management is based for many years on lifestyle intervention and non-insulin glucose-lowering therapies. This long pre-insulin phase represents a crucial clinical window, in which timely recognition of metabolic deterioration, therapeutic inertia, treatment response, and individual risk trajectories may substantially influence long-term outcomes. However, routine care is still frequently based on intermittent assessments, delayed treatment adaptation, and limited integration of clinical, biochemical, behavioral, and digital data. Artificial intelligence may offer a clinically relevant opportunity to move from reactive management to anticipatory care in non-insulin-treated type 2 diabetes. Rather than replacing clinical judgment or automating treatment decisions, artificial intelligence can support clinicians by identifying hidden patterns, predicting metabolic worsening, stratifying risk, improving the interpretation of glucose data, and personalizing follow-up intensity and therapeutic timing. In this setting, its most meaningful role may be to reduce the silent interval between early deterioration and clinical action. This narrative review discusses the rationale, current applications, near-future scenarios, and implementation barriers of artificial intelligence in non-insulin-treated type 2 diabetes. Particular attention is given to advanced interpretation of glycemic data, clinical decision support, prediction of treatment failure, remote monitoring, and the potential integration of multidimensional data into more precise and timely care pathways. The review also emphasizes the need for explainable, clinically validated, equitable, and ethically governed artificial intelligence tools that can be realistically embedded into everyday diabetology practice.